GeroScienceOct 23, 2026

What dog lifespan treatments can teach us about human health

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 24, 2026

Abstract

Existing cardio-renal-metabolic therapies may provide all-cause mortality benefits.

GLP-1 receptor agonists and SGLT2 inhibitors are positioned as potential treatments for lifespan extension.
Challenges to repurposing these drugs include trial duration and regulatory barriers.
Identifying precise surrogate endpoints could help overcome these constraints.
Modifying the 505(b)(2) pathway may allow for faster approval of drugs with proven mortality benefits.
Veterinary medicine's conditional approval framework offers a model for advancing human gerotherapeutics.

Simplified

The growing evidence that existing cardio-renal-metabolic therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors, confer all-cause mortality benefits has positioned them as the first wave of potential gerotherapeutics. However, repurposing these drugs for a lifespan extension indication remains constrained by trial duration, misaligned incentives, and the lack of a viable regulatory path. We highlight two parallel strategies to address these barriers: (1) identifying and validating precise surrogate endpoints, and (2) modifying the 505(b)(2) pathway to allow accelerated approval of already-approved drugs with demonstrated mortality benefit and favorable post-marketing safety. Veterinary medicine's expanded conditional approval framework already applies these strategies, offering precedent for human gerotherapeutics development.

Full Text

Full text is available at the source.

View Full Text ↗

What dog lifespan treatments can teach us about human health

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief